Additional Study Information: The purpose of this clinical trial is to evaluate safety of the trial treatment, its effects on the immune system and on urothelial cancer. The trial treatment includes INO-5401 + INO-9012 delivered by electroporation in combination with TECENTRIQ (Atezolizumab). INO-5401 + INO 9012 is a DNA based therapy that has been created in a lab using the DNA sequence for genes of interest. Genes are the pieces of DNA that act as instructions to make specific proteins that are important for the makeup or function of a cell. They also instruct the cells to make specific proteins that help your immune system to react against cancer cells. INO-5401 plasmids have code for three proteins which are similar to proteins commonly present on cancer cells. This may help your immune system to help fight your cancer. Atezolizumab is an antibody (a protein produced by the body's immune system) that affects the immune system by blocking the programmed deathligand 1 (PD-L1) pathway. The PD-L1 pathway is involved in regulating the bodys natural immune response, but tumors can take advantage of this regulation to partially resist or evade the immune system. By blocking the PD L1 pathway, atezolizumab may help your immune system stop or reverse the growth of tumors. All the drugs used in this trial are given to you in the hospital by trained hospital staff. CELLECTRA 2000 is a device that will deliver three small electric charges through 5 needles to help the entry of the plasmids into your muscle cells.